R
Reshape Biotech
World's first AI and robotics powered imaging and analysis platform, researchers can finally automate visual assays and accelerate the pace of research
About Reshape Biotech
Reshape Biotech, established in 2018 and headquartered in Copenhagen, Denmark, is at the forefront of laboratory automation, specializing in integrating artificial intelligence and robotics to enhance research and development processes in biotechnology. Their mission centers on providing scientists with advanced tools that automate repetitive tasks, streamline data collection, and deliver precise insights, thereby accelerating scientific discoveries.
The company's flagship offerings include a connected platform of intuitive devices and AI-driven analysis tools. These devices capture high-quality data and instantly transmit it to the cloud, where real-time AI analysis begins immediately. This seamless integration allows for automated imaging and analysis throughout incubation, resulting in faster outcomes, elimination of manual labor, and improved data quality. By automating plate-based assays, applying AI-powered analysis, and achieving reproducibility at scale, Reshape Biotech enables laboratories to focus on critical research while the system manages data collection and analysis.
Reshape Biotech's solutions cater to various industries, including agriculture, industrials, food and ingredients, and personal care and cosmetics. Their technology facilitates automated competition assays for pesticide development, high-throughput microbial discovery, functional ingredient characterization, and product quality testing, among other applications. By standardizing experiments across sectors, Reshape Biotech provides a unified platform that enhances efficiency and collaboration in scientific research.
The company's impact is evident in its collaborations with leading organizations. For instance, Chr. Hansen, a global bioscience company, reported a 400% increase in throughput with accurate AI analysis using Reshape Biotech's platform. Similarly, DTU Biosustain's Genome Engineering Group highlighted the platform's ability to provide deep insights, facilitating the discovery of new phenomena more rapidly.
Reshape Biotech's commitment to innovation and excellence has attracted significant investment, including backing from Y Combinator and other prominent investors. Their interdisciplinary team, comprising experts in microbiology, computer vision, hardware, and software development, collaborates closely to redefine laboratory workflows and set new standards in lab automation and software.
By combining automation with real-time AI analysis, Reshape Biotech empowers laboratories to operate more efficiently, make informed decisions, and scale their operations effortlessly, ultimately contributing to advancements in biotechnology and related fields.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Kongens Lyngby, Denmark
- Employees
- 63
- Open positions
- None listed
- Dealroom signal
- 63.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Imaging, Core AI, Medical Robots, Clinical Decision Support
- Technology
- Artificial Intelligence, Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2024 | $20M | $80M | R7 Partners · Astanor Ventures · Y Combinator · Nicholas Francis | ↗ |
| SEED✓Equity / VC | Feb 2023 | $7.1M | $28M | Nicholas Francis · Per Falholt · ACME Capital · Y Combinator | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Reshape Biotech is 8.9K monthly website visits, up 3.5% over the last three months. Reshape Biotech's team declined 4.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Y Combinator
FundersClub
Nicholas Francis- PFPer Falholt
ACME Capital
Look Up Ventures
Series A3 investors entered at this stage
R7 Partners
Astanor Ventures
21St.Bio
Other known investors3 additional known investors
Charlie Songhurst
Investbridge Capital
VOLA Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Reshape Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Reshape Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







